Pharmaceutical company Pharmaxis (ASX:PXS, NASDAQ:PXSL) today announced completion of the first component of its Phase III international trial assessing the effectiveness of Bronchitol in people with cystic fibrosis.

Full Release - Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis